Last Build Date: Tue, 22 Mar 2016 08:29:07 +0100
Sun, 20 Mar 2016 18:07:32 +0100Purpose: Collagen isomerization is a non-enzymatical process associated with tissue aging, and changes in levels of isomerized peptide fragments may reflect unique changes during pathological conditions. The D-G sequence in the collagen type II neoepitope C2M is likely to undergo beta-isomerization over time, and may be altered in tissue turnover in diseases affecting the joint. We therefore hypothesize that pathological conditions, such as osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), in which the anabolic/catabolic balance of cartilage is challenged, may result in altered levels between isomerized and normal collagen type II. (Source: Osteoarthritis and Cartilage)
Sat, 19 Mar 2016 01:34:48 +0100BACKGROUND CONTEXT: Ankylosing spondylitis (AS) can result in severe cervicothoracic kyphotic deformity (CTKD). Few studies have addressed the relationship between cervical osteotomy and health-related quality of life (HRQOL) scores. (Source: The Spine Journal)
Fri, 18 Mar 2016 04:00:00 +0100(Institute for Quality and Efficiency in Health Care) Drug manufacturer presented no relevant data and claimed no added benefit. Notable was the non-publication of literature searches and analyses. (Source: EurekAlert! - Medicine and Health)
Fri, 18 Mar 2016 00:00:00 +0100Conclusions: SLE, IBD and RA are associated with higher risks of HZ compared to older adults recommended for vaccination, suggesting that individuals with these conditions as young as age 40 could potentially benefit from vaccination. This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Fri, 18 Mar 2016 00:00:00 +0100(Source: Arthritis Care and Research)
Fri, 18 Mar 2016 00:00:00 +0100(Source: Arthritis Care and Research)
Thu, 17 Mar 2016 23:37:01 +0100CONCLUSION: This longitudinal observational study, based on a clinical practice setting, showed that remission and MDA are achievable targets in axPsA treated with anti-TNF. Predictors of remission and MDA were also identified. PMID: 26980581 [PubMed - as supplied by publisher] (Source: Journal of Rheumatology)
Thu, 17 Mar 2016 00:00:00 +0100Publication date: Available online 15 March 2016 Source:Joint Bone Spine Author(s): Mehmet Gazi Boyaci, Kamil Tunay, Usame Rakip, Mustafa Karademir, Ergun Karavelioglu (Source: Joint Bone Spine)
Thu, 17 Mar 2016 00:00:00 +0100Conclusion. In this study of TNFi-treated AS patients in clinical practice, current and previous smokers had significantly poorer patient-reported outcomes at baseline, shorter treatment adherence and poorer treatment response compared with never smokers. (Source: Rheumatology)
Wed, 16 Mar 2016 00:00:00 +0100Patient-reported outcome (PRO) measures are an important component to assessing disease impact and therapy response in patients with psoriatic arthritis (PsA). Overall, there are few PsA-specific PROs. Most PROs used in PsA are borrowed from other diseases (eg, rheumatoid arthritis and ankylosing spondylitis) or general population PROs. PROs are used in PsA clinical trials and in the clinical management of PsA. In this review, we discuss the most commonly used PRO in PsA, including their inclusion in composite measures. Future studies may be helpful to determine the best performing PROs in patients with PsA. (Source: Rheumatic Disease Clinics of North America)
Sun, 13 Mar 2016 07:23:02 +0100CONCLUSION: Calisthenic exercises can be easily performed both at home and in hospital setting. In patients with AS, calisthenic exercises performed at the hospital may improve the mobility, and psychological status (anxiety). PMID: 26966823 [PubMed - as supplied by publisher] (Source: Journal of Back and Musculoskeletal Rehabilitation)
Sun, 13 Mar 2016 07:23:02 +0100CONCLUSION: Femoral cartilage thickness is similar between PsA patients and healthy controls. The femoral cartilage thickness in PsA patients is associated with disease activity, functional inadequacy, and enthesopathy scores. PMID: 26966818 [PubMed - as supplied by publisher] (Source: Journal of Back and Musculoskeletal Rehabilitation)
Sat, 12 Mar 2016 16:23:26 +0100MAUI, HAWAII – The most important development within the past year in the treatment of ankylosing spondylitis was the Food and Drug Administration approval of secukinumab (Cosentyx) as the first... (Source: Rheumatology News)
Sat, 12 Mar 2016 00:00:00 +0100HLA-B27 is having strong association to ankylosing spondylitis (AS) and other inflammatory diseases collectively known as seronegative spondyloarthropathy. In literature, although the evidence for association between AS and periodontitis as well as AS and HLA-B27 are there but the association of aggressive periodontitis in HLA-B27 positive patient with AS are not there. We hypothesize that there may be a common pathogenesis in aggressive periodontitis and ankylosing spondylitis in HLA-B27 patient. (Source: Medical Hypotheses)
Sat, 12 Mar 2016 00:00:00 +0100Conclusion One-year treatment costs varied considerably between medications and indications. Some newly approved agents had lower costs but further research is needed to confirm these estimates as more patients are treated. Funding Immunex (a wholly owned subsidiary of Amgen Inc.) and Wyeth (acquired by Pfizer). (Source: Advances in Therapy)
Fri, 11 Mar 2016 00:00:00 +0100Conclusions We summarized the characteristics of backfill and found that backfill is a specific sign of axial SpA seen on T1SE MRI. (Source: Joint Bone Spine)
Fri, 11 Mar 2016 00:00:00 +0100The objective of this subset analysis of the ASCEND trial was to compare the efficacy of etanercept and sulfasalazine in treating patients with AS from Asia, Eastern/Central Europe, and Latin America. A total of 287 patients, 190 receiving etanercept 50 mg once weekly and 97 receiving sulfasalazine 3 g daily, from eight countries were included in this subset analysis. Differences in disease activity and patient-reported outcomes assessing health-related quality-of-life (HRQoL) parameters in response to treatment were analyzed using the Cochran–Mantel–Haenszel test for categorical efficacy endpoints and analysis of covariance model for continuous variables. At week 16, a significantly greater proportion of patients receiving etanercept achieved ASAS20 (79.0 %) compared with patients ...
Thu, 10 Mar 2016 00:00:00 +0100Conclusions The results suggest that it is the presence of rare syntenic SEC16A and MAMDC4 deletions that increases susceptibility to AxSpA in family members who carry the HLA-B*27 allele. (Source: Annals of the Rheumatic Diseases)
Wed, 09 Mar 2016 10:49:51 +0100Cosentyx launched as first-line systemic indication for psoriasis in UK in 2015 and recently approved for psoriatic arthritis and ankylosing spondylitis in Europe (Source: Pharmacy Europe)
Wed, 09 Mar 2016 00:00:00 +0100Conventional DXA imaging of spine and hip to measure bone mineral density (BMD) has limitations in patients with ankylosing spondylitis (AS). We investigated the correlation of hip and spine BMD measurements in patients with AS to determine if hip DXA will prove clinically useful while avoiding the confounding effect of spinal disease. Also, we studied risk factors for osteoporosis (OP) and osteopenia in AS. (Source: Seminars in Arthritis and Rheumatism)
Tue, 08 Mar 2016 00:00:00 +0100Conclusion The metabolome variations in feces indicated AS and RA were two homologous diseases that could not be distinguished by 1H NMR metabolomics. (Source: Metabolomics)
Tue, 08 Mar 2016 00:00:00 +0100Conclusion Notable cervical compensation exists in AS patients with thoracolumbar kyphosis. The cervical compensation responsive to global imbalance was mediated by T1 slope. AS patients with hyperlordotic cervical spine present with better QOL than patients with kyphotic cervical spine. (Source: European Spine Journal)
Mon, 07 Mar 2016 00:00:00 +0100Nature Reviews Nephrology 12, 217 (2016). doi:10.1038/nrneph.2016.18 Authors: Stephen R. Holdsworth, Poh-Yi Gan & A. Richard Kitching Biological therapeutics (biologics) that target autoimmune responses and inflammatory injury pathways have a marked beneficial impact on the management of many chronic diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and ankylosing spondylitis. Accumulating data suggest that a growing number of renal diseases result from (Source: Nature Reviews Nephrology)
Sun, 06 Mar 2016 00:17:05 +0100Authors: Laza IM, Hervella M, DE-LA-Rúa C PMID: 26932994 [PubMed - in process] (Source: Journal of Rheumatology)
Sun, 06 Mar 2016 00:17:05 +0100Authors: Dogan T, Agilli M PMID: 26932992 [PubMed - in process] (Source: Journal of Rheumatology)
Sun, 06 Mar 2016 00:17:05 +0100CONCLUSION: Serum VEGF did not predict radiographic progression/spinal inflammation in patients receiving antitumor necrosis factor. PMID: 26932345 [PubMed - as supplied by publisher] (Source: Journal of Rheumatology)
Sat, 05 Mar 2016 09:07:21 +0100Conclusion: In this large series of patients with SpA, female gender and African-Brazilian ethnicity, as well as predominant axial symptoms, were associated with impaired quality of life. (Source: Revista Brasileira de Reumatologia)
Thu, 03 Mar 2016 12:00:16 +0100The effect of TNF inhibitors on ankylosing spondylitis reached maximum efficacy and stabilized only after 6 months of treatment, twice the time recommended in widely followed guidelines. Medscape Medical News (Source: Medscape Medical News Headlines)
Thu, 03 Mar 2016 00:00:00 +0100Conclusion Our registry data showed that TNF blocker failed to affect the radiographic progression over 5 years in AS patients. (Source: Joint Bone Spine)
Tue, 01 Mar 2016 06:00:00 +0100We reported relative risks and 95% confidence intervals from direct meta-analysis and 95% credible intervals from Bayesian network meta-analysis, and ranked the treatment for outcomes. We also used Grading of Recommendations Assessment, Development and Evaluation criteria to appraise quality of evidence. Fourteen RCTs comprising 2672 active AS patients were included in the network meta-analysis. Most biologic therapy regimens were more effective than placebo regarding all the outcomes assessed, except for secukinumab and tocilizumab. No differences between biologic therapies in the treatment of AS could be found, except for the finding that infliximab 5 mg was superior to tocilizumab. Infliximab 5 mg/kg had the highest probability of being ranked the best for achieving ASAS20, whereas...
Tue, 01 Mar 2016 00:00:00 +0100Conclusions The neoplastic process may be considered as an extraordinary complication of THA and might just be coincidental or the result of some derangement of the healing process in host tissue with no definitely proven hypothesis that the implants or their by-products are carcinogenic. The soluble chemical substances from the implanted prosthetic material are, at least in animals, suspected to play a vital role in the pathogenesis of the neoplastic transformation of the bone tissue. The presented case shall alert orthopedic surgeons to clinical, radiologic, and macroscopic similarities between a malignant tumor and benign lesions caused by wear debris at THA sites. At the examination of plane X-rays of patients with THA loosening, the differential diagnosis should always incl...
Mon, 29 Feb 2016 00:00:00 +0100Conclusions Patient's and their relatives interpretation of familial aggregation, HLAB27, heredity, and risk perception in relation with ankylosing spondylitis involves four broad interpretive units spanning from clinical symptoms to heredity and decisions made accordingly. Their thoughts and consequent decisions are often in contradiction with the medical knowledge on the role of genetic factors in ankylosing spondylitis. (Source: Chronic lllness)
Mon, 29 Feb 2016 00:00:00 +0100Abstract The aim of our study was to evaluate effectiveness of ultrasound treatment applied with exercise therapy in patients with ankylosing spondylitis. Fifty-two patients, who were diagnosed according to modified New York criteria, were aged 25–60, and have spine pain, were randomly assigned to two groups. Ultrasound (US) and exercise therapy were applied to treatment group (27); placebo US treatment and exercise therapy were applied to control group (25). Patients were evaluated before treatment, at the end of treatment, and 4 weeks after the treatment. Daily and night pain, morning stiffness, patient global assessment (PGA), doctor global assessment (DGA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Ba...
Mon, 29 Feb 2016 00:00:00 +0100Authors: Schittenhelm RB, Sivaneswaran S, Lim Kam Sian TC, Croft NP, Purcell AW Abstract Expression of HLA-B27 is strongly associated with ankylosing spondylitis (AS) and other spondyloarthropathies. While this is true for the majority of HLA-B27 allotypes, HLA-B*27:06 and HLA-B*27:09 are not associated with AS. These two subtypes contain polymorphisms that are ideally positioned to influence the bound peptide repertoire. The existence of disease inducing peptides (so-called arthritogenic peptides) has therefore been proposed that are exclusively presented by disease-associated HLA-B27 allotypes. However, we have recently demonstrated that this segregation of allotype-bound peptides is not the case and that many peptides that display sequence features predicted to favor binding to ...
Sat, 27 Feb 2016 11:19:58 +0100We report the histological change after tumor necrosis factor α blocker therapy in patient with amyloid A amyloidosis and nephrotic syndrome secondary to underlying ankylosing spondylitis. The patient achieved complete remission of nephrotic syndrome after 17 months of etanercept treatment. We performed the second kidney biopsy after 40 months, and there was little change in the degree of amyloid deposition in the mesangial area and capillary loops compared with the first biopsy. The interstitial inflammation and foot process effacement, however, were fully recovered. (Source: JCR: Journal of Clinical Rheumatology)
Sat, 27 Feb 2016 01:35:05 +0100PASS syndrome is a rare inflammatory disease characterized by a chronic-relapsing course of pyoderma gangrenosum, acne vulgaris, hidradenitis suppurativa and ankylosing spondylitis. Here, we describe a case of a patient with spontaneously recurrent purulent skin lesions along with seronegative spondylarthritis consistent with the PASS syndrome. During his disease exacerbation, the patient displayed episodes of fever along with elevated serum levels of interleukin (IL)-1β. Skin lesions were characterized by sterile neutrophilic infiltrates and showed a rapid response to the IL-1 receptor antagonist anakinra (Kineret®) consistent with the autoinflammatory nature of this disease. However, unlike other autoinflammatory diseases such as PAPA and PAPASH, we did not find mutations in the gene P...
Thu, 25 Feb 2016 05:50:02 +0100CONCLUSIONS: Added to being asked about the quantity of pain, patients with AS should be questioned about how pain affects their lives. Such an approach can guide health care workers in planning and applying health care approaches specific to each patient. PMID: 26902427 [PubMed - as supplied by publisher] (Source: Contemporary Nurse)
Thu, 25 Feb 2016 00:00:00 +0100To compare the blood loss during primary total hip arthroplasty (THA) between ankylosing spondylitis (AS) and hip osteoarthritis (OA). (Source: The Journal of Arthroplasty)
Wed, 24 Feb 2016 22:20:02 +0100Authors: Slobodin G, Eshed I Abstract The term non-radiographic axial spondyloarthritis (nrAxSpA) was coined for patients who have a clinical picture of ankylosing spondylitis (AS) but do not exhibit radiographic sacroiliitis. The ASAS classification criteria for nrAxSpA, ensuring the recruitment of homogenous study cohorts, were accepted in 2009, although the respective diagnostic criteria for daily clinical practice have not yet been developed. The clinical diagnosis should be based on the composite of clinical symptoms and signs of the disease, HLA B27 status, and magnetic resonance imaging (MRI) of sacroiliac joints. Notably, a negative MRI or HLA B27 does not exclude the diagnosis in patients with a high clinical suspicion for nrAxSpA. The prevalence of nrAxSpA is similar to t...
Wed, 24 Feb 2016 00:00:00 +0100Publication date: Available online 23 February 2016 Source:Joint Bone Spine Author(s): Benjamin Batteux, Agathe Devauchelle, Pauline Lasselin Boyard, Alice Sejourné, Patrice Fardellone, Vincent Goëb (Source: Joint Bone Spine)
Wed, 24 Feb 2016 00:00:00 +0100ConclusionOur findings indicate a high level of dropout among patients receiving full‐dose NSAID therapy in daily practice. In those who tolerated NSAID therapy, there was no clinically relevant decrease in SPARCC scores and low BASDAI50 response. However, we found a decrease in signal intensity of bone marrow edema of the SI joints as an early response to 6 weeks of optimal NSAID therapy in patients newly presenting with axial SpA. (Source: Arthritis and Rheumatism)
Wed, 24 Feb 2016 00:00:00 +0100Advances in pathophysiology and treatment of ankylosing spondylitis (AS) was recently demonstrated. However, the effect of anti-TNF in the newly described inflammatory pathways involved pathogenesis of this di... (Source: Arthritis Research and Therapy)
Tue, 23 Feb 2016 00:00:00 +0100Abstract Crohn’s disease (CD) is a chronic, systemic, immune-mediated inflammation of the gastrointestinal tract. Originally described in 1932 as non-caseating granulomatous inflammation limited to the terminal ileum, it is now recognized as an expanding group of heterogeneous diseases defined by intestinal location, extent, behavior, and systemic extraintestinal manifestations. Joint diseases, including inflammatory spondyloarthritis and ankylosing spondylitis, are the most common extraintestinal manifestations of CD and share more genetic susceptibility loci than any other inflammatory bowel disease (IBD) trait. The high frequency and overlap with genes associated with infectious diseases, specifically Mendelian susceptibility to mycobacterial diseases (MSMD), suggest that CD...
Sat, 20 Feb 2016 19:20:02 +0100Conclusions: According to the literature review, general anesthesia is the most commonly performed anesthetic technique for patients with ankylosing spondylitis undergoing hip surgeries. Special intubation techniques and cautious airway management were very important for these patients. Although both general anesthesia and central neuraxial blockade pose considerable risks to the patients, this case report suggests that combined fascia iliaca block and sciatic nerve block might be a promising option. (Source: Regional Anesthesia and Pain Medicine)
Fri, 19 Feb 2016 06:58:02 +0100CONCLUSIONS: The prevalence of radiographic vertebral fractures was high in AS patients with active disease. Although clinical assessments and BMD improved significantly, new vertebral fractures still developed during 4 years of TNF-α blocking therapy. PMID: 26886385 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Rheumatology)
Fri, 19 Feb 2016 00:00:00 +0100Conclusions: A strong IL‐9/Th9 polarization seems to be the predominant immunological signature of patients with PsA. This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Thu, 18 Feb 2016 05:22:02 +0100CONCLUSIONS: Patients with AS have an almost three-fold increased risk of surgical intervention for kidney stones, with similar management, compared to the general population. PMID: 26389795 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Urology)
Thu, 18 Feb 2016 05:07:22 +0100Abstract Ankylosing spondylitis (AS) is a common inherited autoimmune disease. Copy number variation (CNV) of DNA segments has been found to be an important part of genetic variation, and the FCGR3A and FCGR3B gene CNVs have been associated with various autoimmune disorders. The aim of the study was to determine whether CNVs of FCGR3A and FCGR3B were also associated with the susceptibility of AS. A total of 801 individuals including 402 AS patients and 399 healthy controls were enrolled in this study. The copy numbers of FCGR3 gene (two fragments, included FCGR3A and FCGR3B) were measured by AccuCopy™ methods. Chi-square test and logistic regression model were used to evaluate association between FCGR3 gene CNVs and AS susceptibility. P values, odds ratio, and 95 % confidence ...
Thu, 18 Feb 2016 05:07:22 +0100Abstract Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown origin, while both genetic and environmental factors have been demonstrated to be etiologically involved. Recent genome-wide association and replication studies have suggested that anthrax toxin receptor 2 (ANTXR2), interleukin-1 receptor 2 (IL1R2), caspase recruitment domain-containing protein 9 (CARD9), and small nuclear RNA-activating complex polypeptide 4 (SNAPC4) seem to be associated with AS pathogenesis. This case–control study was performed on 349 unrelated AS patients and 469 age- and gender-matched healthy controls, to investigate whether these non-MHC genes (IL1R2 rs2310173, ANTXR2 rs4333130, CARD9 rs4077515, and SNAPC4 rs3812571) influence the AS risk in Iranian population. ANTXR2 rs4...
Thu, 18 Feb 2016 02:38:02 +0100Conclusions AS fibroblasts are characterized by an imbalance between proliferation and apoptosis. DKK-1 may play a role in switching to new bone formation in AS progression. PMID: 26837533 [PubMed - as supplied by publisher] (Source: Connective Tissue Research)
Wed, 17 Feb 2016 23:34:06 +0100CONCLUSION: The AS patients have thinner corneas compared to control subjects, which may be affected by tear disfunction and inflammatory processes. PMID: 26337454 [PubMed - as supplied by publisher] (Source: Seminars in Ophthalmology)
Wed, 17 Feb 2016 17:44:02 +0100Authors: Braun J, Kiltz U, Heldmann F, Baraliakos X Abstract INTRODUCTION: The topic under discussion is of strong relevance to the field of spondyloarthritis (SpA) because, in addition to established biological, there are new promising compounds. The reason for the review is to put all available data together to allow for an overview on recent developments and to especially inform readers about emerging drugs, biologics and small molecules in the field of SpA. AREAS COVERED: This review on new therapies in axial and peripheral SpA comprising psoriatic arthritis (PsA) shows, that, in addition to the established anti-TNF agents infliximab, etanercept, adalimumab, golimumab, certolizumab and the first biosimilar approved in the EU, there are at least two emerging biologics in the...
Wed, 17 Feb 2016 17:43:02 +0100Authors: Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F Abstract INTRODUCTION: TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying antirheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, and may be administered off-label to treat disseminated granuloma annulare systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept. AREAS COVERED: infliximab and adalimumab can induce the development of anti-infliximab (anti-IFX) a...
Wed, 17 Feb 2016 14:27:02 +0100This article reviews recent data on the efficacy and safety of etanercept and is focused on the treatment of non-radiographic axial spondyloarthritis. This article will also discuss the role of etanercept in the context of current and developing treatment options. PMID: 26788837 [PubMed - as supplied by publisher] (Source: Expert Review of Clinical Immunology)
Wed, 17 Feb 2016 14:27:02 +0100Authors: Gelfer G, Perry L, Deodhar A Abstract Axial spondyloarthritis (axSpA) is a chronic, immune-mediated inflammatory disease of the axial skeleton that includes ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Patients with AS experience chronic pain due to sacroiliac joint and spinal inflammation, and may develop spinal ankylosing with syndesmophyte formation. Tumor necrosis factor α inhibitors (TNFi) have shown promise in the management of AS and axSpA by targeting the underlying inflammatory process, and providing symptomatic relief. Whether they alter the progression of the disease is uncertain. Golimumab is a fully human IgG1 monoclonal antibody that targets and downregulates the pro-inflammatory cytokine TNF-α. The use of golimumab h...
Wed, 17 Feb 2016 14:27:02 +0100CONCLUSION: Efficacy, safety and PK data are highly comparable between CT-P13 and RMP, both in head-to-head clinical studies, and indirect comparisons with historical clinical data for RMP. PMID: 26395833 [PubMed - in process] (Source: Expert Review of Clinical Immunology)
Wed, 17 Feb 2016 14:25:02 +0100CONCLUSIONS: Anti-TNF-α medication and/or avoidance of nonsteroidal anti-inflammatory drugs could improve the thickness of both the corneal epithelium and stroma in AS patients. PMID: 26731089 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Wed, 17 Feb 2016 14:25:02 +0100CONCLUSIONS: The most prominent finding was a worse visual prognosis in herpetic AU, which is probably related to higher prevalence of corneal scarring and glaucoma. In addition, herpetic AU patients have more ocular complications overall. PMID: 26133756 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Wed, 17 Feb 2016 14:25:02 +0100Authors: Tas A, Yolcu U, Ilhan A, Gundogan FC PMID: 26110632 [PubMed - in process] (Source: Ocular Immunology and Inflammation)
Wed, 17 Feb 2016 14:25:02 +0100Regarding Comments by Yolcu et al. on "Evaluation of Choroidal Thickness in Ankylosing Spondylitis Using Optical Coherence Tomography". Ocul Immunol Inflamm. 2015 Dec;23(6):464-5 Authors: Kola M, Kalkisim A, Karkucak M, Turk A, Capkin E, Can I, Serdar OF, Mollamehmetoglu S, Ayar A PMID: 25760919 [PubMed - in process] (Source: Ocular Immunology and Inflammation)
Wed, 17 Feb 2016 14:22:02 +0100Authors: Li D, Guo B, Wu H, Tan L, Chang C, Lu Q Abstract Systemic lupus erythematosus (SLE) is a complicated autoimmune disease of multifactorial pathoaetiology. One of the most serious manifestations is lupus nephritis. The pathogenesis of SLE has not been well elucidated, but it has been reported that interleukin-17 (IL-17) and Th17 cells play important roles in the pathogenesis of SLE. IL-17A, a member of IL-17 family, amplifies the immune response by inducing the local production of chemokines and cytokines, recruiting neutrophils and monocytes, augmenting the production of autoantibodies, and aggravating the inflammation and damage of target organs such as the kidney in SLE. In recent years, several IL-17A pathway inhibitors have advanced into clinical trials, including the a...
Wed, 17 Feb 2016 14:22:02 +0100CONCLUSION: Current literature suggests that increased levels of citrullinated proteins are found in several if not all inflammatory diseases. In RA measurement of anti-citrullinated protein antibodies (ACPA) against citrullinated protein fragments are widely used as a prognostic biomarker. More recently, it has been indicated that levels of selected citrullinated proteins carries additional potential as biomarkers. This includes citrullinated vimentin which provide prognostic information in diseases as fibrosis and ankylosing spondylitis. In addition, recent studies suggest that inhibition of PAD is a target for treatment of diseases such as RA and cancer where proteins that are citrullinated are believed to influence the disease activity. PMID: 25520183 [PubMed - indexed for MEDLINE]...
Wed, 17 Feb 2016 00:00:00 +0100We present two cases of patients with AS who sustained cervical fracture dislocation and spinal cord injury. The ossified sharp fragments caused oesophageal perforation, and the delayed diagnoses had serious consequences. Oesophageal perforation should be suspected in patients with AS and cervical fracture if bone fragments are pressing against the oesophagus and a gas shadow is visible around the fracture site on computed tomography imaging. (Source: Journal of International Medical Research)
Tue, 16 Feb 2016 00:00:00 +0100Conclusions: Physical functioning in routinely TNFi treated AS patients improved up to 6 months and stabilized thereafter. Therefore, it would be better to extend the period of evaluation of TNFi treatment to 6 months rather than the 3 months currently used. The risk factors of long‐term physical functioning found in this study might help to identify patients‐at‐risk at an earlier stage and improve treatment strategy. This article is protected by copyright. All rights reserved. (Source: Arthritis Care and Research)
Tue, 16 Feb 2016 00:00:00 +0100CONCLUSIONS: Periodontal medicine now constitutes an important part of clinical periodontal research. Research activity in periodontal medicine has grown continuously since the early 2000's, and exploration of registers gives a useful up-to-date snapshot of this constantly evolving field of research. This article is protected by copyright. All rights reserved. PMID: 26881700 [PubMed - as supplied by publisher] (Source: Journal of Clinical Periodontology)
Mon, 15 Feb 2016 00:00:00 +0100CONCLUSION: Five predictive factors of this SD were identified, which should be assessed in routine with patients with CIRD receiving biologic treatment: pain, treatment history, self-administration of injections, negative beliefs about treatment, and a lack of perceived medical and social support. PMID: 26879361 [PubMed - as supplied by publisher] (Source: J Rheumatol)
Mon, 15 Feb 2016 00:00:00 +0100CONCLUSION: Fatigue is associated with disease-related factors and mostly with SpA activity. However, the emotional component and sex may contribute to the onset of fatigue. PMID: 26879350 [PubMed - as supplied by publisher] (Source: J Rheumatol)
Mon, 15 Feb 2016 00:00:00 +0100CONCLUSION: This prospective longitudinal observational cohort study showed that after 2 years of ETN, BMD of the hip and spine increased significantly, but the number of patients with VFx and the severity of VFx increased as well. Besides that, radiological progression, including the thoracic spine, increased significantly. Thus, the favorable bone-preserving effect is accompanied by unfavorable outcomes on VFx and radiological damage. PMID: 26879348 [PubMed - as supplied by publisher] (Source: J Rheumatol)
Mon, 15 Feb 2016 00:00:00 +0100The National Institute for Health and Care Excellence (NICE) is a government body that decides which drugs and treatments are available on the NHS in England and Wales. A number of anti-TNF therapies have now been recommended for use within the NHS as treatments for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis (nr-axSpA). Non-radiographic axial spondyloarthritis differs from ankylosing spondylitis, as there is no X-ray evidence of structural damage, meaning it can often go unrecognised for years. New guidance issued by NICE has endorsed the therapies as options for patients who have failed to respond to other forms of treatment, opening up new avenues for those affected by the most severe forms of the disease. New recommendations The guidance recommend...
Sun, 14 Feb 2016 15:29:02 +0100Authors: Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y Abstract Biopharmaceuticals or 'biologics' have revolutionized the treatment of many diseases. However, some patients generate an immune response to such drugs, potentially limiting clinical efficacy and safety. Infliximab (Remicade(®)) is a monoclonal antibody used to treat several immune-mediated inflammatory disorders. A biosimilar of infliximab, CT-P13 (Remsima(®), Inflectra(®)), has recently been approved in Europe for all indications in which infliximab is approved. Approval of CT-P13 was based in part on extrapolation of clinical trial data from two indications (rheumatoid arthritis and ankylosing spondylitis) to all other indications, including inflammatory bowel disease. This review discusses the validity ...
Sun, 14 Feb 2016 14:09:02 +0100Authors: Wendling D Abstract INTRODUCTION: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic condition. Pharmacological treatment relies on nonsteroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs (in case of peripheral involvement) and anti-TNF agents in case of inadequate response. To date, there are no alternate options, and about 30% of the patients do not adequately respond to anti-TNF therapy. AREAS COVERED: This overview is based on recent publications and programmed studies. The author provides the reader with an overview of AS, its current management and provide details of novel insights into the disorder. From there, the authors highlight novel treatments under investigation before providing their expert opinion on the field. EXPE...
Sat, 13 Feb 2016 13:54:02 +0100The objective of this study is to evaluate, under the actual conditions of use, dosing patterns of adalimumab, etanercept, golimumab and infliximab in these pathologies, and compare them with the label regimens recommended, as well as evaluating the financial implications of these regimen modifications. The study population included all adult patients diagnosed with RA, PSA or AS who had been treated with adalimumab, etanercept, golimumab and infliximab for at least 6 months between 1 January 2011 and 31 December 2013. The main variable of this study was to assess the dose dispensed for drugs administered subcutaneously and the dose prepared/administered for drugs administered intravenously, and the annual costs of the treatment. A total of 5,428 episodes were included. The mean weekly dos...
Sat, 13 Feb 2016 13:53:03 +0100CONCLUSIONS: Infliximab has higher cost to the VHA than adalimumab or etanercept. PMID: 26337538 [PubMed - in process] (Source: Journal of Medical Economics)
Wed, 10 Feb 2016 00:00:00 +0100Conclusions Current smoking is associated with an impaired response to TNFi in axSpA. (Source: Annals of the Rheumatic Diseases)
Tue, 09 Feb 2016 20:15:02 +0100CONCLUSION: In patients with rigid sagittal spinal deformities due to ankylosing spondylitis, lumbar lordosis and sagittal balance can be obtained using PSO. PMID: 26854051 [PubMed - in process] (Source: Acta Orthopaedica et Traumatologica Turcica)
Tue, 09 Feb 2016 01:00:33 +0100Authors: Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S. (Source: NIHR Journals Library)
Mon, 08 Feb 2016 00:00:00 +0100Abstract Knowledge is an important factor in patients with ankylosing spondylitis regarding the adoption of appropriate behaviours and education. The aim of this study was to culturally adapt and validate “The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire” for the Portuguese population with ankylosing spondylitis. The Portuguese version of “The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire” was administered to a sample of 180 subjects, from which 63 individuals responded. The adaptation process involved translation, back-translation and submission to a committee of experts in the area, culminating with a Portuguese version of the instrument. Next, the scale reliability a...
Mon, 08 Feb 2016 00:00:00 +0100Conclusion. In this prospective cohort study, no gender-attributable differences in disease activity or physical function over time were found. However, radiographic damage was more severe in males. Furthermore, males had a better QoL over time. (Source: Rheumatology)
Sat, 06 Feb 2016 03:51:02 +0100CONCLUSIONS: In this longstanding AS cohort, the presence of EAMs was not associated with functional disability, QoL or radiographic damage over time, except for IBD, which was associated with a better EuroQoL. PMID: 26843505 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Rheumatology)
Fri, 05 Feb 2016 16:09:02 +0100CONCLUSION: Cyclosporine in monotherapy confirmed its efficacy in cutaneous psoriasis and suggested to be effective also on PsA, reducing spinal and peripheral joints' signs and symptoms. PMID: 26837484 [PubMed - as supplied by publisher] (Source: Giornale Italiano di Dermatologia e Venereologia)
Thu, 04 Feb 2016 00:00:00 +0100We examined 60 AS patients without CV disease or risk factors and 50 healthy controls. Disease activity was evaluated using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS), whereas functional capacity was evaluated using the Bath Ankylosing Spondylitis Functional Index (BASFI). Serum OPG levels were measured with the enzyme-linked immunosorbent assay. Carotid-femoral pulse wave velocity (PWV) was used as an indicator of arterial stiffness, whereas CIMT (examined via carotid ultrasonography) was used to evaluate preclinical atherosclerosis. The mean serum OPG level, PWV, and CIMT were significantly higher in AS patients than in controls (106.7 ± 50.9 vs. 58.1 ± 12.7 pg/mL; 7.4 ± 1.8 vs. 6.2 ± ...
Wed, 03 Feb 2016 00:00:00 +0100Authors: Suh YS, Kim HO, Cheon YH, Jo W, Hong J, Lee SI PMID: 26842104 [PubMed - as supplied by publisher] (Source: The Korean Journal of Internal Medicine)
Mon, 01 Feb 2016 06:00:00 +0100Conclusion. More than 10% of patients had fractures in more than 1 region of the spine. There is a high risk of adverse events in this population, and 6.6% of patients died during their inpatient stay. These results provide clinicians with a better understanding of the distribution and the high morbidity and mortality of fractures in the ankylosed spine. Level of Evidence: 3 (Source: Spine)
Mon, 01 Feb 2016 00:00:00 +0100CONCLUSION: AS might increase the risk of a subsequent newly diagnosed depressive disorder, anxiety disorder, or sleep disorder, but not schizophrenia or bipolar disorder. These observations highlight the need for psychiatric evaluation and intervention for patients with AS. PMID: 26834219 [PubMed - as supplied by publisher] (Source: J Rheumatol)
Mon, 01 Feb 2016 00:00:00 +0100CONCLUSION: High-quality evidence indicates that both traditional and COX-2 NSAID are efficacious for treating axSpA, and harms are not different from placebo in the short term. Various NSAID are equally effective. PMID: 26834216 [PubMed - as supplied by publisher] (Source: J Rheumatol)
Mon, 01 Feb 2016 00:00:00 +0100This study confirms an increased but different level of CKLF1 in RA, OA and AS patients, all significantly higher than that in controls. Additionally, the significant positive correlations between CKLF1 levels and CRP/ESR in RA and between CKLF1 and ESR suggest that CKLF1 might contribute to the inflammation state and clinical symptoms in these rheumatic diseases. Further studies are required to investigate the utility of targeting specific CKLF1 for symptom control or disease modification in RA and AS. (Source: Journal of Huazhong University of Science and Technology -- Medical Sciences --)
Mon, 01 Feb 2016 00:00:00 +0100Authors: Del Rosso A, Maddali-Bongi S Abstract Mind body therapies (MBT) share a global approach involving both mental and physical dimensions, and focus on relationship between brain, mind, body and behavior and their effects on health and disease. MBT include concentration based therapies and movement based therapies, comprising traditional Oriental practices and somatic techniques. The greatest part of rheumatic diseases have a chronic course, leading to progressive damages at musculoskeletal system and causing physical problems, psychological and social concerns. Thus, rheumatic patients need to be treated with a multidisciplinary approach integrating pharmacological therapies and rehabilitation techniques, that not should only aim to reduce the progression of damages at muscul...
Mon, 01 Feb 2016 00:00:00 +0100CONCLUSION: We concluded that multidimensional exercise program should be taken into consideration for AS patients due to its positive effects on symptoms and antiinflammatory effects. PMID: 26850804 [PubMed - in process] (Source: Complementary Therapies in Clinical Practice)
Mon, 01 Feb 2016 00:00:00 +0100(Source: PharmacoEconomics and Outcomes News)
Sat, 30 Jan 2016 12:04:25 +0100Conclusion. More than 10% of patients had fractures in more than 1 region of the spine. There is a high risk of adverse events in this population, and 6.6% of patients died during their inpatient stay. These results provide clinicians with a better understanding of the distribution and the high morbidity and mortality of fractures in the ankylosed spine. Level of Evidence: 3 (Source: Spine)
Sat, 30 Jan 2016 00:00:00 +0100Authors: Beringer A, Noack M, Miossec P Abstract Interleukin-17 (IL-17) is a cytokine which elicits protection against extracellular bacterial and fungal infections and which plays important roles in inflammation. However, when produced in excess, it contributes to chronic inflammation associated with many inflammatory and autoimmune disorders. This has made IL-17 an attractive therapeutic target. The present review describes the structure of the IL-17 family, the IL-17 receptor complex, and the cells producing IL-17. The contributions of IL-17 to disease as well as new IL-17-based treatment options are discussed. Finally, the results of IL-17 or IL-17 receptor inhibitors in clinical trials are detailed. With a fruitful outlook, drug registration has been granted for psoriasis, and...
Fri, 29 Jan 2016 00:00:00 +0100Conclusion Treatment with the anti-TNF drugs adalimumab, etanercept and infliximab is effective and well tolerated in patients with AS. The improvement in disease activity, functional parameters and quality of life was sustained for 12 months. (Source: Rheumatology and Therapy)
Fri, 29 Jan 2016 00:00:00 +0100New research has demonstrated the potentially significant long-term benefits that golimumab therapy can provide for people with psoriatic arthritis.The international study, led by the University of California, San Diego, aimed to evaluate long-term outcomes in psoriatic arthritis patients who achieved or did not achieve minimal disease activity over five years of golimumab treatment.This placebo-controlled trial lasted 24 weeks and was followed by an open-label extension period of up to five years. Results from the study were published in the medical journal Arthritis Care and Research.It was shown that treatment with golimumab yielded significantly higher response rates in terms of achieving minimal disease activity levels compared to those on placebo at weeks 14, 24 and 52, with minimal ...
Thu, 28 Jan 2016 11:49:02 +0100CONCLUSIONS: Etoricoxib provided a clear clinical improvement in around a third of patients with axial AS refractory to traditional NSAIDs. Special care should be required when deciding to start anti-TNF-α therapy; it seems reasonable to keep in mind these results of etoricoxib treatment. PMID: 26812050 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Rheumatology)
Thu, 28 Jan 2016 11:49:02 +0100CONCLUSIONS: The decreased SOCS1 and increased SOCS3 expression in AS PBMCs and T cells, and their correlation with patient's functional ability, acute-phase reactants and serum pro-inflammatory cytokines suggested that SOCS may participate in the pathogenesis of AS. PMID: 26812031 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Rheumatology)
Thu, 28 Jan 2016 00:00:00 +0100CONCLUSION: Our results suggest that both a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, cooperatively play a role in the development of AS. PMID: 26827189 [PubMed - as supplied by publisher] (Source: Cytokine)
Wed, 27 Jan 2016 13:30:00 +0100(MedPage Today) -- No differences in immunogenicity were observed, authors say (Source: MedPage Today Geriatrics)
Wed, 27 Jan 2016 00:00:00 +0100Conclusion Among patients with chronic back pain for ≥3 months beginning at age <45 years, the presence of ≥1 of 3 SpA features is an effective way to identify patients with possible axSpA. This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Wed, 27 Jan 2016 00:00:00 +0100Conclusion: The rate of uveitis flares was lower for axSpA patients treated with CZP than PBO during the randomized controlled phase. Incidence of uveitis flares remained low to Wk96 and was comparable to rates reported for AS patients receiving other anti‐TNF antibodies. This article is protected by copyright. All rights reserved. (Source: Arthritis Care and Research)
Wed, 27 Jan 2016 00:00:00 +0100Conclusions The VDR gene TaqI polymorphism G allele may be a risk factor in AS susceptibility. (Source: Osteoporosis International)